

Media Release

FOR IMMEDIATE RELEASE

Contact Synosia Therapeutics

In Europe:

Julie Walters at Media Speak

Tel: +44 (0) 1494 753 990

Mobile +44 (0) 775 3626967

julie.walters@mediaspeak.com

In US:

Michele Parisi at Media Speak

Tel: +1 925 864 5028

michele.parisi@mediaspeak.com

Synosia Therapeutics Announces Appointment of Vice President of Clinical Research and Development

South San Francisco CA, November 5, 2007 - Synosia Therapeutics today announced the appointment of Uwe Meya, M.D., as the company's new vice president of clinical research and development, effective immediately.

Dr Meya, who joins Synosia's Basel operation, is a neurologist and psychiatrist by training with an impressive track record of more than 20 years in pharmaceutical research and development, focused on disorders of the central nervous system (CNS). His experience spans multiple CNS indications and covers the full spectrum of drug development from first-in-man through to regulatory filing.

At Novartis, Meya managed a team of researchers in CNS clinical development and was a member of a special CNS clinical development management team, overseeing projects from late pre-clinical studies through to the end of Phase I.

Most recently he was at Roche as head of research portfolio management in Basel, where he contributed to the global strategic direction of all therapeutic areas. Meya also served at Roche as clinical research and licensing liaison manager in CNS and received the Roche Global Development Leadership Reward in recognition of his effectiveness in building relationships and partnerships.

While at Roche and Novartis, Meya worked on several of the compounds subsequently out-licensed to Synosia.

-more-

“Uwe Meya brings a depth of experience in neurology and psychiatry that enhances our already solid capabilities in those areas,” said Synosia Chief Executive Officer and President Ian Massey, “and his recognized effectiveness in building business relationships can only help us as we work with our current partners at Novartis, Roche and Syngenta and eventually look for partners to commercialize products for larger markets.”

“It’s an exciting time to be joining Synosia with four compounds entering phase 2 studies in 2008 and another preparing to enter a proof-of-concept study” said Meya. “I’ve felt that CNS is ready for a new approach in development, and I appreciate Synosia’s method of using smart, efficient proof-of-concept studies to gain predictive data moving into full phase 2 trials.”

Meya was educated in Germany and studied medicine in Aachen, Germany and in Glasgow, Scotland. He received his medical degree from the University of Aachen, where he also completed a doctorate in psychiatry, before undertaking clinical service to become a board-qualified neurologist and psychiatrist.

He is a member of the European College of Neuropsychopharmacology and is a founding member of the International College of Geriatric Psychoneuropharmacology, where he served as a council member for more than three years.

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta, including two marketed drugs that will be tested in new indications, extending their reach into new therapeutic areas with combined sales potential in excess of \$2.5 billion. Synosia has offices in Basel, Switzerland, and South San Francisco, CA.

Synosia Therapeutics has raised \$32.5 million funding from Versant Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures (Menlo Park, CA) and Novo A/S (Copenhagen, Denmark). For more information, visit www.synosia.com.

#